C34, a membrane fusion inhibitor, blocks HIV infection of Langerhans cells and viral transmission to T cells

Journal of Investigative Dermatology

Volumn 127, Issue 6, 2007, Pages 1436-1443

  Sugaya, Makoto ^a   Hartley, Oliver ^b   Root, Michael J ^c   Blauvelt, Andrew ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; C PEPTIDE C 34; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 41; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; EXPLANT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INCUBATION TIME; INFECTION PREVENTION; LANGERHANS CELL; MEMBRANE FUSION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; SEXUAL TRANSMISSION; SKIN CULTURE; SKIN EPITHELIUM; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIGENS, CD34; CELLS, CULTURED; COCULTURE TECHNIQUES; EPIDERMIS; GENE PRODUCTS, GAG; HIV; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; LANGERHANS CELLS; MEMBRANE FUSION; RANTES; T-LYMPHOCYTES; VIRUS INTEGRATION; ZIDOVUDINE;

EID: 34248593768     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700736     Document Type: Article

References (44)

1. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quinones-Mateu ME et al. (2003) Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 77:1021-38
2. Chan DC, Chutkowski CT, Kim PS (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 95:15613-7
3. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-73
4. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R et al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-62
5. Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, Bush TJ et al. (2004) In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 48:3834-44
6. Furuta RA, Wild CT, Weng Y, Weiss CD (1998) Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 5:276-9
7. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J et al. (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-97
8. Hartley O, Gaertner H, Wilken J, Thompson D, Fish R, Ramos A et al. (2004) Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA 101:16460-5
9. Hu J, Gardner MB, Miller CJ (2000) Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 74:6087-95
10. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T et al. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240-3
11. Jiang S, Lin K, Strick N, Neurath AR (1993) HIV-1 inhibition by a peptide. Nature 365:113
12. Kawamura T, Bruse SE, Abraha A, Sugaya M, Hartley O, Offord RE et al. (2004) PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol 78:7602-9
13. Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB et al. (2000) Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 192:1491-500
14. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM et al. (2003) R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 100:8401-6
15. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B et al. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175-85
16. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M et al. (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186-95
17. Lederman MM, Offord RE, Hartley O (2006) Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 6:371-82
18. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M et al. (2004) Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485-7
19. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-77
20. Lu M, Blacklow SC, Kim PS (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2:1075-82
21. Malashkevich VN, Chan DC, Chutkowski CT, Kim PS (1998) Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci USA 95:9134-9
22. Markosyan RM, Cohen FS, Melikyan GB (2003) HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell 14:926-38
23. Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, Bax R (2004) A randomized Phase I vaginal safety study of three concentrations of C31G vs Extra Strength Gynol II. Contraception 70:233-40
24. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS (2000) Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151:413-23
25. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R (1998) Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 140:315-23
26. Munoz-Barroso I, Salzwedel K, Hunter E, Blumenthal R (1999) Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol 73:6089-92
27. Neurath AR, Strick N, Jiang S, Li YY, Debnath AK (2002) Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect Dis 2:6
28. Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE et al. (2003) Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother 47:509-17
29. Patton DL, Sweeney YC, Cummings PK, Meyn L, Rabe LK, Hillier SL (2004) Safety and efficacy evaluations for vaginal and rectal use of BufferGel in the macaque model. Sex Transm Dis 31:290-6
30. Pierson TC, Doms RW (2003) HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 281:1-27
31. Piguet V, Blauvelt A (2002) Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. J Invest Dermatol 119:365-9
32. Rimsky LT, Shugars DC, Matthews TJ (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72:986-93
33. Root MJ, Steger HK (2004) HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 10:1805-25
34. Royce RA, Sena A, Cates W, Cohen MS (1997) Sexual transmission of HIV. N Engl J Med 336:1072-8
35. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM et al. (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-5
36. Sugaya M, Lore K, Koup RA, Douek DC, Blauvelt A (2004) HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters. J Immunol 172:2219-24
37. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, Schmidt A et al. (2004) Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retrov 20:11-8
38. Turville SG, Arthos J, Mac Donald K, Lynch G, Naif H, Clark G et al. (2001) HIV gp120 receptors on human dendritic cells. Blood 98:2482-8
39. Turville SG, Cameron PU, Handley A, Lin G, Pohlmann S, Doms RW et al. (2002) Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 3:975-83
40. UNAIDS (2006) AIDS epidemic update: December 2006.
41. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-7
42. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M et al. (2005) Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438:99-102
43. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-30
44. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 91:9770-4